glaucoma Avellino Labs Begins Commercial Push for Expanded Ophthalmology Genetic Test Panel Premium The company has launched an updated test called AvaGen that returns diagnostic subtype results for corneal dystrophies and polygenic risk scores for keratoconus. Combination of Sequencing, EHR Data Links Genes to Range of Conditions The exome-by-phenome-wide analysis uncovered 21 novel gene-phenotype associations, including genes linked to glaucoma and diabetes. Mouse Vision Restored A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports. Glaucoma Protective Variants Uncovered in Genetic Data From UK, Finland With UK Biobank and FinnGenn data, researchers tracked down rare changes in the angiopoietin-like 7 gene that coincide with lower glaucoma and intraocular pressure risk. PLOS Papers on Glaucoma Gene, Cold-Tolerant Yeast Origins, Myanmar Bloodstream Infection Bacteria In PLOS this week: gene alteration linked to glaucoma, genome sequencing traces origin of lager yeast, and more. May 21, 2018 Glaucoma Risk Factor Linked to More Than 100 Genetic Loci in Europeans Feb 8, 2018 Q Biomed Options Glaucoma Biomarker From WUSTL Oct 2, 2017 CRISPR Editing in Mice Disrupts Glaucoma-Causing Gene Mutation Jan 11, 2016 Through GWAS Meta-Analysis, Researchers Link Three Genes to Glaucoma Sep 10, 2015 Two Risk Genes Interact to Cause Primary Open-Angle Glaucoma Jun 26, 2014 Quark Begins Enrollment in Glaucoma Drug Trial Premium Oct 31, 2013 Sylentis Sees Phase III Trial for Glaucoma Drug by 2015 Premium Oct 15, 2013 UCSD-led Glaucoma Genes Study Lands $6.4M Apr 18, 2013 NIH Awards Nearly $2M in microRNA Research Grants Premium Jul 5, 2012 Sylentis Preps to Move Glaucoma Drug into Phase II Next Year Premium May 3, 2012 Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma Premium Feb 9, 2012 Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion Premium Jan 12, 2012 Quark Releases Positive Phase I Data on Ocular Neuroprotectant Premium Nov 17, 2011 Sylentis Picks up Option to Alnylam RNAi IP Premium Sep 13, 2010 Decode-Led GWAS Uncovers Glaucoma Risk Variant Jul 8, 2010 Sylentis Concludes Phase Ia Study of Glaucoma Drug Premium Apr 1, 2010 Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners Premium Mar 4, 2010 Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant Premium Dec 3, 2009 Quark Aims for Five Clinical Indications, New IND in 2010 Premium Aug 20, 2009 Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September Premium Load More Breaking News In Brief This Week: Illumina, Personalis, Proteomedix, and More Ancient DNA Details Population Dynamics Within Andean Tiwanaku Civilization Genomic Data Spanning 2K Years Gives Glimpse of Etruscan Origins, Population Changes People in the News: New Appointments at Hologic, Akoya Biosciences, Caris Life Sciences, More At NSGC, Genetic Counselors Address Race-Based Medicine, Ways to Change New Products Posted to GenomeWeb: Becton Dickinson, Cosmos-ID, OncoDNA, More The Scan US Booster Eligibility Decision The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions. Arizona Bill Before Judge The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction. Additional Genes Wales is rolling out new genetic testing service for cancer patients, according to BBC News. Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.